Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.…
The Buyout Behind Roth/MKM’s Call on Rapid Micro Biosystems (RPID)
Rapid Micro Biosystems (NASDAQ: RPID) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 171 employees.
The shares were at 0.7350 USD on 20 November 2026, down 76.3% over 52 weeks. Its 52-week range is 0.5801 USD to 4.940 USD: the price is 85.1% below the high and 26.7% above the low.
Its market capitalisation is 37.37M USD.
Rapid Micro Biosystems reports return on equity of -141.9%, an operating margin of -131.0% and revenue up 21.6% year over year.
Its debt exceeds its cash by 16.52M USD, a debt-to-equity ratio of 0.72. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.